Bellus Health shares are trading higher after the company announced its Phase 2b SOOTHE trial of BLU-5937 achieved its primary endpoint.

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.